The miR-99 family regulates the DNA damage response through its target SNF2H

Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, VA, USA.
Oncogene (Impact Factor: 8.56). 04/2012; 32(9). DOI: 10.1038/onc.2012.131
Source: PubMed

ABSTRACT Chromatin remodeling factors are becoming known as crucial facilitators of recruitment of repair proteins to sites of DNA damage. Multiple chromatin remodeling protein complexes are now known to be required for efficient double strand break repair. In a screen for microRNAs (miRNAs) that modulate the DNA damage response, we discovered that expression of the miR-99 family of miRNAs correlates with radiation sensitivity. These miRNAs were also transiently induced following radiation. The miRNAs target the SWI/SNF chromatin remodeling factor SNF2H/SMARCA5, a component of the ACF1 complex. We found that by reducing levels of SNF2H, miR-99a and miR-100 reduced BRCA1 localization to sites of DNA damage. Introduction of the miR-99 family of miRNAs into cells reduced the rate and overall efficiency of repair by both homologous recombination and non-homologous end joining. Finally, induction of the miR-99 family following radiation prevents an increase in SNF2H expression and reduces the recruitment of BRCA1 to the sites of DNA damage following a second dose of radiation, reducing the efficiency of repair after multiple rounds of radiation, as used in fractionated radiotherapy.Oncogene advance online publication, 23 April 2012; doi:10.1038/onc.2012.131.

Download full-text


Available from: Adam Christopher Mueller, Nov 06, 2014
  • Source
    • "(For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) 17 miR-421, miR-101 and miR-100, which then activate cell cycle checkpoint [36] [37] [38] [39]. The down-regulation of miR-106b regulates p21-dependent G2/M cell cycle arrest [40]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: DNA double-strand breaks (DSBs) are among the most deleterious DNA lesions, which if unrepaired or repaired incorrectly can cause cell death or genome instability that may lead to cancer. To counteract these adverse consequences, eukaryotes have evolved a highly orchestrated mechanism to repair DSBs, namely DNA-damage-response (DDR). DDR, as defined specifically in relation to DSBs, consists of multi-layered regulatory modes including DNA damage sensors, transducers and effectors, through which DSBs are sensed and then repaired via DNAprotein interactions. Unexpectedly, recent studies have revealed a direct role of RNA in the repair of DSBs, including DSB-induced small RNA (diRNA)-directed and RNA-templated DNA repair. Here, we summarize the recent discoveries of RNA-mediated regulation of DSB repair and discuss the potential impact of these novel RNA components of the DSB repair pathway on genomic stability and plasticity. Copyright © 2015 Elsevier B.V. All rights reserved.
    DNA repair 05/2015; DOI:10.1016/j.dnarep.2015.04.017 · 3.36 Impact Factor
  • Source
    • "Their analysis revealed 37 downregulated and 14 upregulated miRs in PCa specimens. Among downregulated microRNAs miR-16, miR-99, and let-7 family are well known tumor-suppressor genes [39] [40] [41] [42]. Interestingly , reduced levels of miR-205, miR-100, and miR-30 family were observed only in hormone-refractory specimens suggesting a hypothetical prognostic role for CRPC prediction. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Prostate cancer (PCa) is one of the leading causes of cancer-related death in men. Despite considerable advances in prostate cancer early detection and clinical management, validation of new biomarkers able to predict the natural history of tumor progression is still necessary in order to reduce overtreatment and to guide therapeutic decisions. MicroRNAs are endogenous noncoding RNAs which offer a fast fine-tuning and energy-saving mechanism for posttranscriptional control of protein expression. Growing evidence indicate that these RNAs are able to regulate basic cell functions and their aberrant expression has been significantly correlated with cancer development. Therefore, detection of microRNAs in tumor tissues and body fluids represents a new tool for early diagnosis and patient prognosis prediction. In this review, we summarize current knowledge about microRNA deregulation in prostate cancer mainly focusing on the different clinical aspects of the disease. We also highlight the potential roles of microRNAs in PCa management, while also discussing several current challenges and needed future research.
    BioMed Research International 09/2014; 2014:146170. DOI:10.1155/2014/146170 · 2.71 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Radiation oncology modalities such as intensity-modulated and image-guided radiation therapy can reduce the high dose to normal tissue and deliver a heterogeneous dose to tumors focusing on areas deemed at highest risk for tumor persistence. Clinical radiation oncology produces daily doses ranging from 1 to 20 Gy, with tissues being exposed to 30 or more daily fractions. Hypothesizing that cells that survive fractionated radiation therapy have a substantially different phenotype than the untreated cells, which might be exploitable for targeting with molecular therapeutics or immunotherapy, three prostate cancer cell lines (PC3, DU145 and LNCaP) and normal endothelial cells were studied to understand the biology of differential effects of multi-fraction (MF) radiation of 0.5, 1 and/or 2 Gy fraction to 10 Gy total dose, and a single dose (SD) of 5 and 10 Gy. The resulting changes in mRNA, miRNA and phosphoproteome were analyzed. Significant differences were observed in the MF radiation exposures including those from the 0.5 Gy MF that produces little cell killing. As expected, p53 function played a major role in response. Pathways modified by MF include immune response, DNA damage, cell cycle arrest, TGF-β, survival and apoptotic signal transduction. The radiation-induced stress response will set-forth a unique platform for exploiting the effects of radiation therapy as "focused biology" for cancer treatment in conjunction with molecular targeted or immunologically directed therapy. Given that more normal tissue is treated, albeit to lower doses with these newer techniques, the response of the normal tissue may also influence long-term treatment outcome.
    Molecular Cancer Research 11/2012; 11(1). DOI:10.1158/1541-7786.MCR-12-0492 · 4.50 Impact Factor
Show more